Detailed Mechanism Funding and Narrative

Years of mechanism: 2011 2012 2013 2014 2015 2016 2017 2018

Details for Mechanism ID: 13317
Country/Region: Uganda
Year: 2015
Main Partner: Joint Clinical Research Center
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: USAID
Total Funding: $1,424,623 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $382,605
Care: TB/HIV (HVTB) $70,726
Care: Pediatric Care and Support (PDCS) $47,748
Laboratory Infrastructure (HLAB) $250,000
Testing: HIV Testing and Counseling (HVCT) $23,158
Treatment: Adult Treatment (HTXS) $612,997
Treatment: Pediatric Treatment (PDTX) $37,389
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2016 6,923
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2016 703
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2016 13,518
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2016 835
CARE_CURR Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 21,979
CARE_CURR Sum of Aggregated Age/Sex disaggregates 2016 21,979
CARE_NEW Aggregated Age/sex: <15 Female 2016 50
CARE_NEW Aggregated Age/sex: <15 Male 2016 44
CARE_NEW Aggregated Age/sex: 15+ Female 2016 864
CARE_NEW Aggregated Age/sex: 15+ Male 2016 470
CARE_NEW Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 1,428
CARE_NEW Sum of Aggregated Age/sex disaggregates 2016 1,428
CARE_NEW Sum of Aggregated Age/sex disaggregates 2016 1,428
FN_THER Aggregated Age: <18 2016 203
FN_THER Aggregated Age: 18+ 2016 324
FN_THER Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period 2016 527
FN_THER Number of PLHIV who were nutritionally assessed and found to be clinically undernourished 2016 6,594
FN_THER Sum of Aggregated Age disaggregates 2016 527
LAB_ACC Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation 2016 1
LAB_CAP By clinical laboratories 2016 1
LAB_CAP By Point-of-care testing sites 2016 4
LAB_CAP Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests 2016 1
TB_ART Aggregated Age: <15 2016 2
TB_ART Aggregated Age: 15+ 2016 24
TB_ART Female 2016 17
TB_ART Male 2016 9
TB_ART Sum of Aggregated Age disaggregates 2016 26
TB_ART Sum of Sex disaggregates 2016 26
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2016 32
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2016 26
TB_SCREEN Aggregated Age - USE WITH HQ PERMISSION ONLY: <15 2016 1,539
TB_SCREEN Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+ 2016 20,440
TB_SCREEN Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 21,979
TB_SCREEN Sex: Female 2016 14,352
TB_SCREEN Sex: Male 2016 7,627
TB_SCREEN Sum of Aggregated Age disaggregates 2016 21,979
TB_SCREEN Sum of Sex disaggregates 2016 21,979
TB_SCREEN The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period 2016 21,979
TX_CURR Aggregated Age/Sex: 15+ Female 2016 6,046
TX_CURR Aggregated Age/Sex: 15+ Male 2016 13,137
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2016 20,707
TX_CURR Sum of Aggregated Age/Sex 15+ 2016 19,183
TX_CURR Sum of Aggregated Age/Sex disaggregates 2016 19,183
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2016 294
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2016 623
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2016 956
TX_NEW Sum of Aggregated Age/Sex disaggregates 2016 917
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2016 495
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2016 582
Cross Cutting Budget Categories and Known Amounts Total: $440,000
Human Resources for Health $400,000
Key Populations: Sex Workers $40,000
Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Training of health workers and community outreach workers
Collection and use of strategic information on SWs and clients
Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Monitoring and evaluation of SW programs
Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs